title: An experimental study on the therapy of infantile hemangioma with recombinant interferon γ.
abstract: OBJECTIVE
  The purpose of this investigation was to study the effect of interferon γ (IFN-γ) in the treatment of infantile hemangioma.
  
  
  METHODS
  Hemangioma tissue excised from a 4-month-old female infant who underwent surgery were separated into small nubs (4 × 4 × 5mm(3)) and implanted subcutaneously into nude mice (2 nubs per mouse). Thirty-two surviving hemangioma nubs were randomly divided into 2 groups, an IFN-γ-administered group (16) and a control group (16). Interferon γ or saline solution was injected subcutaneously, and the growth of hemangioma in the nude mice was monitored. Proliferation and apoptosis of hemangioma were tested by immunohistochemistry and real-time polymerase chain reaction.
  
  
  RESULTS
  Seven days after IFN-γ injection, the hemangiomas in the IFN-γ-administered group were significantly smaller than that in the control group (P < .01). The proliferation cytokine Ki-67 mRNA in the IFN-γ group was significantly lower than that in the control group (P < .05). DAPK-1 mRNA in the IFN-γ group was significantly higher than that in the control group (P < .05). Cell apoptosis expression in the IFN-γ group was significantly more than that in controls (P < .05).
  
  
  CONCLUSIONS
  Exogenous IFN-γ can treat hemangioma effectively in a nude mice model. Its mechanism was closely related to both inhibition of hemangioma proliferation and acceleration of its apoptosis.
authors.affiliation: Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
authors.forename: Qiang
authors.initials: Q
authors.lastname: Peng
authors.forename: Wenying
authors.initials: W
authors.lastname: Liu
authors.forename: Fang
authors.initials: F
authors.lastname: Zhou
authors.forename: Yuanxiang
authors.initials: Y
authors.lastname: Wang
authors.forename: Yi
authors.initials: Y
authors.lastname: Ji
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D051017:Apoptosis Regulatory Proteins / Q000096:biosynthesis / Q000235:genetics; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000096:biosynthesis / Q000235:genetics; D002455:Cell Division; D064550:Death-Associated Protein Kinases; D005260:Female; D018324:Hemangioma, Capillary / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D007223:Infant; D007279:Injections, Subcutaneous; D007371:Interferon-gamma / Q000008:administration & dosage / Q000627:therapeutic use*; D019394:Ki-67 Antigen / Q000096:biosynthesis / Q000235:genetics; D051379:Mice; D008819:Mice, Nude; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000235:genetics; D012333:RNA, Messenger / Q000096:biosynthesis; D012334:RNA, Neoplasm / Q000096:biosynthesis; D011897:Random Allocation; D017471:Receptors, Interferon / Q000096:biosynthesis / Q000235:genetics; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D040521:Subcutaneous Tissue; D023041:Xenograft Model Antitumor Assays; D000096743:Interferon gamma Receptor
chemical_list: D020533:Angiogenesis Inhibitors; D051017:Apoptosis Regulatory Proteins; D017871:Calcium-Calmodulin-Dependent Protein Kinases; D064550:Death-Associated Protein Kinases; D007155:Immunologic Factors; D007371:Interferon-gamma; D019394:Ki-67 Antigen; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D017471:Receptors, Interferon; D011994:Recombinant Proteins; D000096743:Interferon gamma Receptor; C498355:Mki67 protein, mouse; C579096:DAPK1 protein, human; C579106:Dapk1 protein, mouse